Evidence map›Paper›PMID 38707707›Full record

ArticleBrain communications2024

CSF neurofilament light chain profiling and quantitation in neurological diseases.

Claire A Leckey, John B Coulton, Tatiana A Giovannucci, Yingxin He, Aram Aslanyan, Rhiannon Laban, Amanda Heslegrave, Ivan Doykov, Francesca Ammoscato, Jeremy Chataway and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Brain communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Moving toward precision and personalized treatment strategies in psychiatry.The international journal of neuropsychopharmacology · 2025
    Review
  6. Article
  7. Biomarkers in Hereditary Spastic Paraplegias.International journal of molecular sciences · 2025
    Review
  8. Observational
  9. Article
  10. Exercise to Counteract Alzheimer's Disease: What Do Fluid Biomarkers Say?International journal of molecular sciences · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Claire A LeckeyDementia Research Centre, UCL Queen Square Institute of Neurology, University College London, London, WC1N 3BG, UK.
John B CoultonDepartment of Neurology, Washington University School of Medicine, Washington University in St Louis, St Louis, MO 63110, USA.ORCID https://orcid.org/0000-0002-1353-1180
Tatiana A GiovannucciDementia Research Centre, UCL Queen Square Institute of Neurology, University College London, London, WC1N 3BG, UK.ORCID https://orcid.org/0000-0001-8978-6318
Yingxin HeDepartment of Neurology, Washington University School of Medicine, Washington University in St Louis, St Louis, MO 63110, USA.ORCID https://orcid.org/0000-0003-2543-4553
Aram AslanyanDementia Research Centre, UCL Queen Square Institute of Neurology, University College London, London, WC1N 3BG, UK.ORCID https://orcid.org/0000-0003-3220-6313
Rhiannon LabanUK Dementia Research Institute at UCL, University College London, London, WC1E 6BT, UK.
Amanda HeslegraveUK Dementia Research Institute at UCL, University College London, London, WC1E 6BT, UK.
Ivan DoykovTranslational Mass Spectrometry Research Group, UCL Great Ormond Street Hospital Institute of Child Health, University College London, London, WC1N 1EH, UK.ORCID https://orcid.org/0000-0002-4580-6396
Francesca AmmoscatoBarts and the London School of Medicine and Dentistry, Queen Mary University of London, Blizard Institute, Centre for Neuroscience, London, E1 2AT, UK.
Jeremy ChatawayDepartment of Neuroinflammation, Faculty of Brain Sciences, Queen Square Multiple Sclerosis Centre, UCL Queen Square Institute of Neurology, University College London, London, WC1B 5EH, UK.ORCID https://orcid.org/0000-0001-7286-6901
Floriana De AngelisDepartment of Neuroinflammation, Faculty of Brain Sciences, Queen Square Multiple Sclerosis Centre, UCL Queen Square Institute of Neurology, University College London, London, WC1B 5EH, UK.
Sharmilee GnanapavanDepartment of Neurology, Barts Health NHS Trust, London, E1 1BB, UK.
Lauren M ByrneDepartment of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, WC1N 3BG, UK.
Jonathan M SchottDementia Research Centre, UCL Queen Square Institute of Neurology, University College London, London, WC1N 3BG, UK.ORCID https://orcid.org/0000-0003-2059-024X
Edward J WildDepartment of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, WC1N 3BG, UK.
Nicolas R BarthelémyDepartment of Neurology, Washington University School of Medicine, Washington University in St Louis, St Louis, MO 63110, USA.
Henrik ZetterbergUK Dementia Research Institute at UCL, University College London, London, WC1E 6BT, UK.ORCID https://orcid.org/0000-0003-3930-4354
Selina WrayDepartment of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, WC1N 3BG, UK.ORCID https://orcid.org/0000-0003-3062-7050
Randall J BatemanDepartment of Neurology, Washington University School of Medicine, Washington University in St Louis, St Louis, MO 63110, USA.ORCID https://orcid.org/0000-0002-7729-1702
Kevin MillsTranslational Mass Spectrometry Research Group, UCL Great Ormond Street Hospital Institute of Child Health, University College London, London, WC1N 1EH, UK.
Ross W PatersonDementia Research Centre, UCL Queen Square Institute of Neurology, University College London, London, WC1N 3BG, UK.

Funding

Medical Research Council MR/W026686/1
6 · The paper itself

Abstract

Neurofilament light chain is an established marker of neuroaxonal injury that is elevated in CSF and blood across various neurological diseases. It is increasingly used in clinical practice to aid diagnosis and monitor progression and as an outcome measure to assess safety and efficacy of disease-modifying therapies across the clinical translational neuroscience field. Quantitative methods for neurofilament light chain in human biofluids have relied on immunoassays, which have limited capacity to describe the structure of the protein in CSF and how this might vary in different neurodegenerative diseases. In this study, we characterized and quantified neurofilament light chain species in CSF across neurodegenerative and neuroinflammatory diseases and healthy controls using targeted mass spectrometry. We show that the quantitative immunoprecipitation-tandem mass spectrometry method developed in this study strongly correlates to single-molecule array measurements in CSF across the broad spectrum of neurodegenerative diseases and was replicable across mass spectrometry methods and centres. In summary, we have created an accurate and cost-effective assay for measuring a key biomarker in translational neuroscience research and clinical practice, which can be easily multiplexed and translated into clinical laboratories for the screening and monitoring of neurodegenerative disease or acute brain injury.

Indexed as

mass spectrometryneurodegenerative diseasesneurofilament light chain

Identifiers

PMID38707707
PMCPMC11069115

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.